Vir Biotechnology Inc. (VIR) Misses Q4 EPS by 41c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Vir Biotechnology Inc. (VIR) Misses Q4 EPS by 41c

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023 4:05 PM EST

Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact

$1.5 billion of sotrovimab collaboration revenue recognized in 2022

 Strong balance sheet expected to fund Virs robust portfolio through major inflection points with the flexibility to evaluate external opportunities

SAN FRANCISCO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth... More